P/B
1,9
4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
$755.2M
Market Cap • 10/2/2026
2015
(11 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
8,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7,4
EPS
—
Market Cap
Market Cap
755,2M
EV
433,1M
EV/Revenue
4,7
EV/EBITDA
-2,3
EV/EBIT
-2,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-19,4%
Total Yield
-19,4%
Payout
0%
Retained Earnings
-858M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
261,2%
Capex/Revenue
-0,1%
Capex/D&A
-1,3%
Capex/OCF
0,1%
SBC/OCF
—
% PPE
5,9%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
31,9%
CAGR Op. Income 5Y
30,5%
CAGR Net Income 5Y
28%
CAGR EPS 5Y
-9,2%
CAGR OCF 5Y
20,1%
Leverage
N.D./EBITDA
1,7
Debt/Equity
0%
Current Ratio
8
Quick Ratio
7,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!